PDT and the Immune System
DOI link for PDT and the Immune System
PDT and the Immune System book
Worldwide preclinical and clinical studies for more than two decades now have shown that photodynamic therapy (PDT) can be an integral part of a multimodal treatment approach to various cancer types and other malignancies. After the FDA’s approval of Photofrin, a commercially available hematoporphyrin derivative, in 1993 for patients with early and advanced stages of lung cancer, research utilizing PDT picked up speed globally. Today, PDT is a clinically approved therapeutic modality that is being successfully used for treatment of neoplastic and nonmalignant diseases.